Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Takaji Wakita and Tadaki Suzuki.
Takaji Wakita
Connection Strength
0.747
Tadaki Suzuki
  1. Potential anti-COVID-19 agents, cepharanthine and nelfinavir, and their usage for combination treatment. iScience. 2021 Apr 23; 24(4):102367.
    View in: PubMed
    Score: 0.234
  2. Severe Acute Respiratory Syndrome Coronavirus 2 Infection among Returnees to Japan from Wuhan, China, 2020. Emerg Infect Dis. 2020 07; 26(7).
    View in: PubMed
    Score: 0.222
  3. Temporal maturation of neutralizing antibodies in COVID-19 convalescent individuals improves potency and breadth to circulating SARS-CoV-2 variants. Immunity. 2021 08 10; 54(8):1841-1852.e4.
    View in: PubMed
    Score: 0.060
  4. Mefloquine, a Potent Anti-severe Acute Respiratory Syndrome-Related Coronavirus 2 (SARS-CoV-2) Drug as an Entry Inhibitor in vitro. Front Microbiol. 2021; 12:651403.
    View in: PubMed
    Score: 0.059
  5. Identification of Anti-Severe Acute Respiratory Syndrome-Related Coronavirus 2 (SARS-CoV-2) Oxysterol Derivatives In Vitro. Int J Mol Sci. 2021 Mar 19; 22(6).
    View in: PubMed
    Score: 0.058
  6. Prevalence of SARS-CoV-2-Specific Antibodies, Japan, June 2020. Emerg Infect Dis. 2021 02; 27(2):628-631.
    View in: PubMed
    Score: 0.058
  7. SARS-CoV-2 Screening Test for Japanese Returnees From Wuhan, China, January 2020. Open Forum Infect Dis. 2020 Jul; 7(7):ofaa243.
    View in: PubMed
    Score: 0.056
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.